| Outcome Measures: |
Primary: Change From Baseline in HbA1c at Week 12, Change from the baseline measurement, where the baseline measurement was obtained at randomization (0 week) before receiving study medication, 12 weeks|Change From Baseline in HbA1c at Week 26, Change from the baseline measurement, where the baseline measurement was obtained at randomization (0 week) before receiving study medication, 26 weeks|Examination of Long-term Safety of Linagliptin (52-week Treatment), The incidence of AEs (Preferred Terms) with a frequency of 5% or more in the patients with type 2 diabetes mellitus who received linagliptin (5 mg or 10 mg) once daily for 52 weeks, 52 weeks | Secondary: Relative Efficacy Response of HbA1c at Week 12, HbA1c value decreased below 7.0%, below 6.5% and reduction from baseline ≥0.5% at Week 12, 12 weeks|Relative Efficacy Response of HbA1c at Week 26, HbA1c value decreased below 7.0%, below 6.5% and reduction from baseline ≥0.5% at Week 26, 26 weeks|Relative Efficacy Response of HbA1c at Week 52, HbA1c value decreased below 7.0%, below 6.5% and reduction from baseline ≥0.5% at Week 52, 52 weeks|Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12, Change from the baseline measurement, where the baseline measurement was obtained at randomization (0 week) before receiving study medication, 12 weeks|Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26, Change from the baseline measurement, where the baseline measurement was obtained at randomization (0 week) before receiving study medication, 26 weeks|Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52, Change from the baseline measurement, where the baseline measurement was obtained at randomization (0 week) before receiving study medication, 52 weeks
|
| Locations: |
1218.23.05 Boehringer Ingelheim Investigational Site, Asahi, Chiba, Japan|1218.23.06 Boehringer Ingelheim Investigational Site, Funabashi, Chiba, Japan|1218.23.21 Boehringer Ingelheim Investigational Site, Hitachinaka, Ibaraki, Japan|1218.23.44 Boehringer Ingelheim Investigational Site, Hitachiota, Ibaraki, Japan|1218.23.09 Boehringer Ingelheim Investigational Site, Imizu, Toyama, Japan|1218.23.45 Boehringer Ingelheim Investigational Site, Inashiki-gun, Ibaraki, Japan|1218.23.13 Boehringer Ingelheim Investigational Site, Izumisano, Osaka, Japan|1218.23.27 Boehringer Ingelheim Investigational Site, Kariya, Aichi, Japan|1218.23.47 Boehringer Ingelheim Investigational Site, Kitakatsushika-gun, Saitama, Japan|1218.23.39 Boehringer Ingelheim Investigational Site, Kitakyuushuu, Fukuoka, Japan|1218.23.02 Boehringer Ingelheim Investigational Site, Koriyama, Fukushima, Japan|1218.23.03 Boehringer Ingelheim Investigational Site, Koriyama, Fukushima, Japan|1218.23.10 Boehringer Ingelheim Investigational Site, Kyoto, Kyoto, Japan|1218.23.37 Boehringer Ingelheim Investigational Site, Marugame, Kagawa, Japan|1218.23.38 Boehringer Ingelheim Investigational Site, Marugame, Kagawa, Japan|1218.23.23 Boehringer Ingelheim Investigational Site, Matsumoto, Nagano, Japan|1218.23.07 Boehringer Ingelheim Investigational Site, Meguro-ku, Tokyo, Japan|1218.23.25 Boehringer Ingelheim Investigational Site, Nagoya, Aichi, Japan|1218.23.26 Boehringer Ingelheim Investigational Site, Nagoya, Aichi, Japan|1218.23.28 Boehringer Ingelheim Investigational Site, Nagoya, Aichi, Japan|1218.23.29 Boehringer Ingelheim Investigational Site, Nagoya, Aichi, Japan|1218.23.30 Boehringer Ingelheim Investigational Site, Nagoya, Aichi, Japan|1218.23.04 Boehringer Ingelheim Investigational Site, Naka, Ibaraki, Japan|1218.23.15 Boehringer Ingelheim Investigational Site, Nishi-ku, Hiroshima, Hiroshima, Japan|1218.23.34 Boehringer Ingelheim Investigational Site, Nishi-ku, Sakai, Osaka, Japan|1218.23.22 Boehringer Ingelheim Investigational Site, Nishishinjyuku, Shinjyuku-ku, Tokyo, Japan|1218.23.16 Boehringer Ingelheim Investigational Site, Oita, Oita, Japan|1218.23.40 Boehringer Ingelheim Investigational Site, Oita, Oita, Japan|1218.23.36 Boehringer Ingelheim Investigational Site, Okayama, Okayama, Japan|1218.23.11 Boehringer Ingelheim Investigational Site, Osaka, Osaka, Japan|1218.23.12 Boehringer Ingelheim Investigational Site, Osaka, Osaka, Japan|1218.23.32 Boehringer Ingelheim Investigational Site, Osaka, Osaka, Japan|1218.23.33 Boehringer Ingelheim Investigational Site, Osaka, Osaka, Japan|1218.23.35 Boehringer Ingelheim Investigational Site, Osaka, Osaka, Japan|1218.23.17 Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido, Japan|1218.23.18 Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido, Japan|1218.23.19 Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido, Japan|1218.23.41 Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido, Japan|1218.23.42 Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido, Japan|1218.23.43 Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido, Japan|1218.23.01 Boehringer Ingelheim Investigational Site, Sendai, Miyagi, Japan|1218.23.20 Boehringer Ingelheim Investigational Site, Sendai, Miyagi, Japan|1218.23.46 Boehringer Ingelheim Investigational Site, Shinjuku-ku, Tokyo, Japan|1218.23.08 Boehringer Ingelheim Investigational Site, Shinjyuku-ku,Tokyo, Japan|1218.23.14 Boehringer Ingelheim Investigational Site, Suita, Osaka, Japan|1218.23.31 Boehringer Ingelheim Investigational Site, Takatsuki, Osaka, Japan|1218.23.48 Boehringer Ingelheim Investigational Site, Yokohama, Kanagawa, Japan
|
